Parabilis filed for an IPO as it prepares for Phase 3 progress on zolucatetide (FOG-001) in desmoid tumors, following a high-value strategic alliance with Regeneron. The IPO plan is framed around funding the Phase 3 registrational trial while continuing earlier clinical development across additional indications. In separate reporting tied to the same timeline, Parabilis said the FDA had granted fast-track designation for desmoid tumors after early tumor-shrinking activity in its prior study. The company’s expansion plan also references continuing clinical work in familial adenomatous polyposis and other solid tumors with Wnt pathway-activating mutations. The Regeneron collaboration adds financial support and development optionality, reinforcing investor appetite for platform-driven programs aimed at intracellular targets previously labeled “undruggable.”